microfluidic impedance device

Additional Info

  • Overview:

    DIMID and DIMID+ Grants


    Development and Commercialization of an Innovative Microfluidic Impedance-based Device for multi-parametric cell analysis


    DIMID Grant

    DIMID+ Grant




    Co-ordinator          Dr. Sadik Hafizovic, CEO, Zurich Instruments AG., Zurich, Switzerland Dr. Sadik Hafizovic, CEO, Zurich Instruments AG., Zurich, Switzerland
    SMEs:  Zurich Instruments AG, Cellix Ltd., Cytognos SL, Labor S.R.L.
    Academic:  Universita Degli Studi di Roma Tor Vergata, University of Southampton, Ecole Polytechnique Federale De Lausanne.
    SMEs:  Zurich Instruments AG, Cellix Ltd., Cytognos SL, Amphasys AG, Lab64 GmbH
    Funding Body EU Commission EU Commission
    Grant Type Research for SMEs (FP7) Research for SMEs (FP7)
    Date 1 October 2011 – 30 September 2013 1 October 2013 – 31 March 2015
    Total Grant Amount €1,056,516 €1,406,929
    Keywords Impedance-based microfluidic cytometer; Disposable biochips  
    Contact This email address is being protected from spambots. You need JavaScript enabled to view it. or phone +353-1-4500-155  
    Project Website www.dimid-project.eu  

    The DIMID project ("Development of an Innovative Microfluidic Impedance-based Device for multi-parametric cell analysis”) is a highly interdisciplinary project where microfluidics, electronics, biology and informatics converge with the main aim of building a low cost impedance cytometer suitable for non-spherical cells and equipped with chips.

    To realize the device, the focus of the first project period was on the conceptual design of the device (a suited chip design in terms of geometry and electrode configuration, a proper stimulation and measuring scheme, a custom signal processing to extract features valuable for discrimination).

    During the last phase of the second project period, the DIMID consortium dedicated its efforts to the system integration and verification.  A first complete DIMID system prototype was built at the premises of CELLIX with support of all consortium partners. The system was evaluated and several optimizations were done resulting in a second prototype. The second prototype was then used to do preliminary tests with red blood cells (RBC) and to do field tests on specific applications like dairy food quality testing.  The following video (left) gives an overview of the integration aspects of the DIMID device and the picture (right) illustrates the integration of the subcomponents for the device:

    DIMID integration


    Overall DIMID Project Aims:
    Cell analysis has become an important technique and represents a fast growing market for a wealth of applications in the fields of life sciences, medicine, food and environmental analytics.  While clinical (diagnostic) and research applications in the healthcare and drug discovery markets demand rather complex analyses at the single cell level, routine and quality control applications in food analytics and bioprocess monitoring require simpler, quick and cheap analyses, which work more at the cell population level and provide only low-content average values instead of high-content single cell data.  Many routine and quality control applications, however, would enormously profit from a higher information content of the analysis and make various processes at research and production levels more effective. 
    This will lead to the first low-cost, portable impedance-based microfluidic cytometer equipped with disposable chips, which will enable a range of new analyses and diagnostic approaches that can be performed simply and quickly, without the use of a centralised resource. The system will rely upon the availability of highly accurate and specific disposable microfluidic chips, a high speed electronic control unit and a signal processing software which will allow to timely and accurately retrieve multiparametric information on the analysed sample.
    DIMIDplus Project Aims:
    This DIMIDplus Demonstration Action is a direct follow-on of the DIMID (286692, FP7-SME-2011) project. The DIMID project was successful, on time, finishing in Sep 2013 and both its efficiency and its potential have been proven.  The SMEs form a strong consortium with the potential to market also a complex high-tech product like DIMID.  The SME consortium will now focus on commercialization of the DIMID device,  realised within this Demonstration Activity which is scheduled for 18 months.  The DIMID project will lead to the first prototypes of a low-cost impedance-based cytometer suitable for non-spherical cells.  Based on these prototypes the DIMIDplus consortium aims to commercialize a portable impedance-based microfluidic cytometer equipped with disposable chips.
  • Recommended Products:

    ExiGo Pump

    ExiGo - iPad mini or LabVIEW controlled Microfluidic Pump
    The ExiGo™ pump is a microfluidic syringe pump controlled...